Welcome to the CED Clinic Weekly Literature Radar for September 04, 2026. This weekly index aggregates and translates 14 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings.

Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies.

Mainstream Media Claim: News reports frequently frame findings like “Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and” as immediate therapeutic breakthroughs or universal treatment warnings without context.

Primary PubMed / Journal Evidence: Analysis of published data in PubMed provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles.

Dr. Caplan’s Clinical Verdict: Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols.

1. Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.

Source: PubMed (September 04, 2026) | PMID: 42692277 | DOI: 10.1016/j.clindermatol.2026.08.012: Primary Link

Study Design & Cohort: This was a narrative review of clinical trials, pharmacovigilance studies, and case reports and series focused on nonimmunologic injection site and dermatologic reactions with GLP-1 receptor agonists. The authors also analyzed United States FDA Adverse Event Reporting System data for tirzepatide, semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide, and combined injection-site events with skin-related adverse events into an adjusted category for comparison across agents.

Primary Findings: Among 442,567 FDA adverse event reports, 137,412 reports, or 31.0%, involved skin and injection-site reactions, making this the third most frequently reported adverse event category. Exenatide had the highest proportion of skin and injection-site reports at 53.1%, followed by dulaglutide at 33.5%, tirzepatide at 32.6%, liraglutide at 17.1%, semaglutide at 12.2%, and lixisenatide at 6.9%. Common reactions included pain, bleeding, erythema, bruising, mass, pruritus, and swelling, with additional reports of dysesthesias, nodules, granulomatous reactions, bruising, and hyperhidrosis.

Clinical Relevance: In practice, I would counsel patients starting GLP-1 therapy that skin and injection-site reactions are common, usually mild to moderate, and often manageable with supportive care rather than stopping treatment. For patients who develop local reactions, I pay attention to injection technique, site rotation, and symptom control, and I consider agent-specific tolerability when choosing between exenatide, dulaglutide, tirzepatide, liraglutide, semaglutide, and lixisenatide. These reactions matter because they can affect adherence, comfort, and long-term success with weight loss or glycemic control.

2. GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.

Source: PubMed (September 04, 2026) | PMID: 42692107 | DOI: 10.1016/j.oret.2026.08.029: Primary Link

Study Design & Cohort: This was a retrospective cohort study using U.S. private health plan claims data from 2012 to 2024. The investigators applied a target trial emulation framework with a new user design and active comparators, comparing adults with type 2 diabetes who initiated GLP-1 receptor agonists against those who initiated SGLT-2 inhibitors or DPP-4 inhibitors. Propensity score methods and Cox proportional hazards models were used to estimate adjusted hazard ratios for non-arteritic anterior ischemic optic neuropathy (NAION).

Primary Findings: The cohort included 19,505 adults with type 2 diabetes, with 9,213 (47.2%) starting GLP-1 receptor agonists and 10,292 (52.8%) starting SGLT-2i or DPP-4i, and there were 26 NAION events total. Overall GLP-1 receptor agonist use was not significantly associated with higher NAION risk versus SGLT-2i or DPP-4i, with an adjusted hazard ratio of 1.86 (95% CI 0.84 to 4.09). Liraglutide users had a higher NAION risk within 12 to 18 months of follow-up, and the elevated risk signal was also seen in males and older adults.

Clinical Relevance: In practice, I would treat this as a signal that deserves eye symptom screening, especially early after starting liraglutide in older men with diabetes. For patients with prior optic nerve disease or new visual complaints, I would coordinate promptly with ophthalmology and review the full diabetes regimen, since the comparison drugs here were SGLT-2 inhibitors and DPP-4 inhibitors. The absolute event count was low, so this should guide vigilance rather than automatic avoidance of GLP-1 therapy when the metabolic benefits are otherwise strong.

3. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.

Source: PubMed (September 04, 2026) | PMID: 42690639 | DOI: 10.1001/jamaoto.2026.2266: Primary Link

Study Design & Cohort: This is a narrative review of glucagon-like peptide-1 receptor agonists for obstructive sleep apnea, with synthesis of six meta-analyses and the SURMOUNT-OSA phase 3 trials. The review focuses on adults with obesity and moderate to severe OSA, and it discusses tirzepatide, other GLP-1 receptor agonists, and mechanistic preclinical data related to upper airway physiology.

Primary Findings: Across six meta-analyses, GLP-1 receptor agonists were associated with apnea-hypopnea index reductions ranging from 5.7 to 21.9 events per hour. In SURMOUNT-OSA, tirzepatide lowered AHI by 20 to 24 events per hour versus placebo, and 42% to 50% of treated patients reached remission, defined as AHI less than 5 events per hour or less than 15 without symptoms.

Clinical Relevance: For patients with obesity-related OSA, GLP-1 receptor agonists now offer a disease-modifying option that can complement CPAP, improve preoperative readiness before airway surgery, and may help expand candidacy for hypoglossal nerve stimulation. In practice, I would reserve this approach for patients with BMI above 30 who are CPAP-intolerant or who have obesity-related comorbidities, since the benefit is tied mainly to weight loss and is less compelling for patients whose OSA is driven by fixed anatomic obstruction. Tirzepatide is the first FDA-approved medication for moderate to severe OSA in adults with obesity, but CPAP remains more effective for immediate AHI control, and weight regain after stopping therapy is a real issue to plan for.

4. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

Source: PubMed (September 04, 2026) | PMID: 42688617 | DOI: 10.1136/bmjmed-2026-003026: Primary Link

Study Design & Cohort: This was a network meta-analysis of randomized controlled trials evaluating GLP-1 based therapies for weight loss in adults with overweight or obesity without diabetes. The authors searched Embase, PubMed, and Web of Science from 1 January 2000 to 6 March 2026 and included 58 trials with 24,214 participants, comparing GLP-1 receptor agonists and related co-agonists against placebo or active comparators for at least 12 weeks.

Primary Findings: Compared with placebo, the greatest mean weight loss was seen with retatrutide at -22.10% (95% CI -25.60% to -18.60%), followed by tirzepatide at -19.28% (-20.39% to -18.16%) and CagriSema at -17.32% (-19.32% to -15.32%). Conventional GLP-1 receptor agonists produced more modest weight loss, and similar ranking patterns were seen for waist circumference and lipid outcomes. Low certainty evidence suggested higher discontinuation with danuglipron and retatrutide, while mazdutide showed better tolerability.

Clinical Relevance: For patients with obesity who do not have diabetes, the next generation incretin agents appear to deliver the largest weight loss, with tirzepatide and retatrutide leading the field in this analysis. In practice, I would weigh the magnitude of expected weight reduction against tolerability, access, and the limited amount of direct head-to-head evidence, especially when counseling patients about long-term adherence. These data also support monitoring waist circumference and lipids alongside scale weight, since the metabolic benefits track with the weight loss signal.

5. Current therapeutic important and future treatment perspectives of MASH.

Source: PubMed (September 04, 2026) | PMID: 42687024 | DOI: 10.1038/s41586-026-10672-8: Primary Link

Study Design & Cohort: This is a narrative review of the current therapeutic important for metabolic dysfunction-associated steatohepatitis (MASH), with emphasis on late-stage clinical trial data and emerging treatment strategies. The authors synthesize evidence across non-cirrhotic MASH with fibrosis, including pharmacologic classes such as THRβ agonists, GLP-1 receptor agonists, PPAR agonists, FGF21 analogues, incretin-based therapies, glucagon-based therapies, and agents targeting fibrogenesis, inflammation, and the gut-liver axis.

Primary Findings: The review identifies accelerated approval of resmetirom, a thyroid hormone receptor-β agonist, and semaglutide, a GLP-1 receptor agonist, as major therapeutic milestones for patients with non-cirrhotic MASH and fibrosis. It also reports that MASH includes partially overlapping phenotypes, one more liver-centric with accelerated fibrogenesis and liver-related outcomes, and another more cardiometabolic with insulin resistance and higher cardiovascular risk, supporting the need for stratified treatment approaches.

Clinical Relevance: For day-to-day hepatology practice, this supports moving beyond lifestyle counseling alone and considering phenotype-directed therapy in patients with non-cirrhotic MASH and fibrosis. In my view, the practical question is which patient needs a liver-targeted agent like resmetirom, which patient may benefit from an incretin-based approach such as semaglutide, and how to align treatment with cardiometabolic risk, kidney disease, and other medications. Biomarker-guided selection and combination therapy will likely become central as we try to match the right drug to the right MASH subtype.

6. Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities.

Source: PubMed (September 04, 2026) | PMID: 42685919 | DOI: 10.1016/j.clindermatol.2026.08.013: Primary Link

Study Design & Cohort: This is a narrative review of emerging clinical evidence on glucagon-like peptide-1 receptor agonists in dermatology, drawing from clinical trials, observational studies, and real-world analyses. The paper focuses on patients with inflammatory skin disease, especially psoriasis and hidradenitis suppurativa, and examines GLP-1 receptor agonists, including tirzepatide, in the setting of obesity, insulin resistance, metabolic syndrome, and cardiovascular disease.

Primary Findings: Across the cited literature, GLP-1 receptor agonists were associated with improved outcomes in psoriasis and hidradenitis suppurativa, along with reductions in metabolic and cardiovascular comorbidity burden. In psoriasis, combination therapy with tirzepatide was linked to enhanced skin clearance, substantial weight loss, and a reduced risk of psoriatic arthritis. In hidradenitis suppurativa, GLP-1 receptor agonist use was associated with better cardiometabolic outcomes and fewer systemic complications.

Clinical Relevance: From a practical dermatology perspective, these agents may be most useful when inflammatory skin disease is tightly linked to obesity, insulin resistance, and cardiometabolic risk. In my view, the real value is often in treating the metabolic driver, which can improve function, lower systemic risk, and support better long-term disease control. For patients already eligible for GLP-1 therapy, coordination with primary care or endocrinology can help align dosing, weight-loss goals, and comorbidity management with the skin treatment plan.

7. Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.

Source: PubMed (September 04, 2026) | PMID: 42683763 | DOI: 10.1097/MNH.0000000000001225: Primary Link

Study Design & Cohort: This is a narrative review that synthesizes mechanistic, epidemiologic, and therapeutic evidence linking liver disease to the cardiovascular-kidney-metabolic framework. It draws on large cohort data and recent clinical trials across patients with MASLD, CKD, MASH, diabetes, obesity-related HFpEF, and related cardiometabolic disease states, with emphasis on resmetirom, semaglutide, and tirzepatide.

Primary Findings: Large cohort studies show that coexistent MASLD and CKD confer additive, stage-dependent mortality risk that exceeds the risk from either condition alone. Hepatic fibrosis severity, rather than steatosis burden, is the main prognostic driver, and recent trials support benefit from resmetirom in MASH, semaglutide in diabetic and non-diabetic kidney disease and MASH, and tirzepatide in obesity-related HFpEF.

Clinical Relevance: In practice, I would treat liver assessment as part of cardiometabolic risk stratification, especially in patients with CKD, diabetes, obesity, or HFpEF. Validated noninvasive fibrosis tools should be used early in high-risk patients, because fibrosis stage helps guide prognosis and therapy selection, and agents such as resmetirom or incretin-based therapies may fit patients with overlapping liver, renal, and cardiovascular disease. Medication choice still needs attention to renal function, glycemic status, weight goals, and concurrent cardiometabolic therapies, since these drugs are being used across several linked disease states rather than in isolation.

8. Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.

Source: PubMed (September 04, 2026) | PMID: 42683151 | DOI: 10.3389/fphar.2026.1889594: Primary Link

Study Design & Cohort: This is a narrative review of mechanistic and clinical evidence on tirzepatide for obesity without diabetes. The authors synthesize human trial data, translational studies, and preclinical findings in adults with obesity, with tirzepatide evaluated as a dual GIP and GLP-1 receptor agonist.

Primary Findings: The review reports that available human evidence links tirzepatide-associated weight loss primarily to reduced appetite and lower energy intake. Across clinical trials, tirzepatide produced substantial weight reduction and is described as among the most effective obesity management medications, with most comparative data beyond SURMOUNT-5 remaining indirect; the main adverse effects were mild to moderate gastrointestinal symptoms during dose escalation.

Clinical Relevance: For practice, tirzepatide is a high-yield option for patients with obesity who need more than lifestyle therapy alone, especially when meaningful weight loss is the goal. In clinic, I would counsel patients that dose escalation commonly brings nausea, vomiting, or diarrhea, so slow titration and close follow-up matter, and I would still screen carefully for tolerability, long-term safety, and concurrent therapies that may affect GI symptoms or hydration status.

9. Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.

Source: PubMed (September 04, 2026) | PMID: 42682157 | DOI: 10.23876/j.krcp.26.272: Primary Link

Study Design & Cohort: This is a narrative review of incretin-based therapies in diabetic kidney disease and cardio-kidney-metabolic syndrome, synthesizing evidence from cardiovascular outcome trials, the FLOW kidney outcomes trial, and translational mechanistic studies. The paper discusses GLP-1 receptor agonists, dual GIP/GLP-1 agonists such as tirzepatide, and triple incretin agonists such as retatrutide in adults with obesity, type 2 diabetes, and chronic kidney disease.

Primary Findings: The FLOW trial showed a 24% reduction in major kidney outcomes with GLP-1 receptor agonist therapy in patients with type 2 diabetes and chronic kidney disease. Across the broader evidence base, GLP-1 receptor activation is associated with improved metabolic decongestion, better intrarenal hemodynamics, and lower inflammatory and fibrotic signaling, while newer dual and triple incretin agonists produce greater weight loss with emerging cardiovascular and renal benefit signals.

Clinical Relevance: In my practice, this supports using incretin therapy as part of layered CKD care in patients with obesity and type 2 diabetes who still carry residual renal and cardiovascular risk despite SGLT2 inhibitor therapy. These agents are especially attractive when weight loss, glycemic control, and kidney protection all matter, and they fit well into a phenotype-driven approach rather than a glucose-only mindset. For patients with CKD, I would think about GI tolerability, dose escalation, and coordination with other glucose-lowering drugs to reduce hypoglycemia risk while aiming for functional gains such as weight reduction, blood pressure improvement, and slower kidney decline.

10. Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.

Source: PubMed (September 04, 2026) | PMID: 42681751 | DOI: 10.1111/dom.71277: Primary Link

Study Design & Cohort: This is a narrative clinical review that used structured literature identification and outcome-stratified synthesis to evaluate incretin-based therapies across type 2 diabetes, obesity, cardiovascular disease, and chronic kidney disease. The authors integrated evidence by therapeutic class, clinical domain, outcome maturity, and safety boundaries, with emphasis on GLP-1 receptor agonists, dual and triple agonists, amylin-linked agents, and oral small-molecule strategies.

Primary Findings: Selected GLP-1 receptor agonists have hard cardiovascular and renal outcome data, while several dual, triple, amylin-linked, and oral small-molecule approaches are supported mainly by glycemic, weight-loss, metabolic, or early translational endpoints. In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit should be prioritized, and in type 2 diabetes with chronic kidney disease, semaglutide has dedicated kidney outcome evidence. In obesity with cardiometabolic risk, sustained high-magnitude weight reduction is now a clinically relevant endpoint, while receptor-network signaling through GLP-1, GIP, glucagon, and amylin helps explain differences in efficacy and tolerability.

Clinical Relevance: In my practice, these agents should be matched to the phenotype and the outcome we are trying to move, whether that is ASCVD risk reduction, kidney protection, or meaningful weight loss. I would favor GLP-1 receptor agonists with proven outcome data when cardiovascular or renal protection is the priority, and I would be cautious with newer polyagonists until their long-term safety, durability, and lean-mass effects are clearer. Gastrointestinal tolerability, discontinuation effects, and medication access all matter in real-world care, so dosing and follow-up need to be individualized rather than driven by mechanism alone.

11. Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.

Source: PubMed (September 04, 2026) | PMID: 42681675 | DOI: 10.1186/s40842-026-00333-0: Primary Link

Study Design & Cohort: This was a PRISMA-compliant systematic review and random-effects meta-analysis of randomized trials from the COMBINE program in adults with type 2 diabetes inadequately controlled on basal insulin. The pooled analysis included 1,970 participants from COMBINE 1, which compared once-weekly IcoSema with once-weekly insulin icodec, and COMBINE 3, which compared IcoSema with basal-bolus insulin therapy; COMBINE 2 was excluded because it addressed semaglutide monotherapy escalation from GLP-1 receptor agonist treatment.

Primary Findings: Compared with control, IcoSema produced no statistically significant difference in HbA1c reduction, with a pooled mean difference of -0.37% (95% CI -0.95 to 0.21, P = 0.21, I² = 98%). It significantly reduced body weight by 6.10 kg (95% CI -7.21 to -5.00, P < 0.00001) and lowered systolic blood pressure by 2.45 mmHg (95% CI -3.52 to -1.38, P < 0.00001). IcoSema also improved atherogenic lipids, including total cholesterol (ETR 0.97, 95% CI 0.95 to 0.98, P = 0.0001), LDL-C (ETR 0.94, 95% CI 0.90 to 0.98, P = 0.005), triglycerides (ETR 0.94, 95% CI 0.91 to 0.97, P = 0.0006), and VLDL-C (ETR 0.94).

Clinical Relevance: From a practical diabetes care standpoint, IcoSema offers a once-weekly option that can reduce injection burden while improving weight, blood pressure, and lipid parameters that matter for ASCVD risk. In patients already on basal insulin who need intensification, this profile may be attractive when weight gain, adherence, or hypoglycemia risk are major concerns. I would still frame this as a surrogate-endpoint signal, and I would reserve strong cardiovascular claims until dedicated outcome trials confirm event reduction.

12. Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.

Source: PubMed (September 04, 2026) | PMID: 42680805 | DOI: 10.1038/s44324-026-00131-3: Primary Link

Study Design & Cohort: This was an observational study of 63,215 patients with preexisting neuropsychiatric conditions, evaluating 24 incident neuropsychiatric outcomes after treatment initiation. Propensity-matched comparisons assessed semaglutide against metformin, SGLT2 inhibitors, and DPP-4 inhibitors, and a landmark analysis within the semaglutide cohort compared higher versus lower attained dose over the first two years with outcomes in the subsequent two years. Bulk and single-cell transcriptomic analyses were also performed to examine GLP1R expression in central and peripheral nervous system tissues.

Primary Findings: In propensity-matched analyses, semaglutide was associated with lower two-year neuropsychiatric event risk than metformin, SGLT2 inhibitors, and DPP-4 inhibitors. Within semaglutide users, higher attained dose in the pre-landmark period was associated with lower post-landmark incidence of substance-related disorders (P < 0.001), mood disorders (P < 0.001), anxiety- and stress-related disorders (P < 0.001), CNS atrophies (P < 0.001), neuromuscular disorders (P = 0.013), eating/sleep/behavioral disorders (P = 0.022), and personality/impulse-control disorders (P = 0.028). Post-landmark incidence of dementia or CNS degenerative diseases was similar between high-dose and low-dose cohorts (P = 0.15), while cognitive symptoms and speech/language symptoms tracked more closely with weight loss (p < 0.001 and p < 0.003, respectively).

Clinical Relevance: For patients with obesity and preexisting psychiatric or neurologic comorbidity, semaglutide may offer neuropsychiatric advantages that appear dose-related for several diagnostic categories. In practice, I would pay attention to dose escalation, tolerability, and concurrent psychiatric medications, because the signal here suggests that achieved dose may matter more than simply starting therapy. The cognitive and speech findings also remind us to monitor weight loss effects separately from direct drug effects, especially in patients with baseline frailty, eating disorders, or complex neurocognitive symptoms.

13. Whole-exome sequencing in individuals with obsessive-compulsive disorder and chronic tic disorders identifies 36 large-effect risk genes.

Source: PubMed (September 04, 2026) | PMID: 42680906 | DOI: 10.1038/s41593-026-02419-5: Primary Link

Study Design & Cohort: This was a whole-exome sequencing study of 3,964 individuals with obsessive-compulsive disorder, chronic tic disorders, or both, including 2,418 trios. The investigators assessed de novo and rare protein-damaging variants and applied gene-level analyses to identify high-confidence risk genes, with downstream transcriptomic and network analyses to map biological convergence.

Primary Findings: The cohort showed an excess of de novo and rare protein-damaging mutations in cases, and the analysis identified 36 high-confidence risk genes at a false discovery rate below 0.1. Four previously recognized genes were confirmed, CELSR3, CHD8, SCUBE1, and WWC1, and four genes overlapped with OCD genome-wide association study loci, BRWD1, CELSR3, QRICH1, and SYNE1; the implicated genes were enriched in postnatal cerebellum, prenatal and postnatal cortex, and striatum.

Clinical Relevance: For clinicians, this supports OCD and chronic tic disorders as genetically driven neurodevelopmental conditions with shared biology, which may help explain early onset, family clustering, and mixed OCD-tic phenotypes. In practice, this kind of gene discovery does not change first-line treatment today, but it strengthens the rationale for careful phenotyping, family counseling, and future precision-targeted therapies that may emerge from pathways active in cortex, striatum, and cerebellum.

14. Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain.

Source: PubMed (September 04, 2026) | PMID: 42678518 | DOI: 10.1007/s00213-026-07157-x: Primary Link

Study Design & Cohort: This was a prospective, self-selected observational study of 183 adults using edible cannabis for chronic, non-specific low back pain. Participants chose one of three cannabinoid profiles, CBD-dominant, THC-dominant, or mixed CBD to THC, and completed cognitive testing before use, 1 hour after use, and 2 hours after use across executive function, processing speed, memory, working memory, and verbal learning.

Primary Findings: At 1 hour after use, the CBD group performed better than the CBD plus THC group on working memory. The CBD group also showed more stable verbal learning scores after use than the THC and CBD plus THC groups, while no significant effects were seen for executive function, episodic memory, or processing speed. Older age was associated with better baseline working memory in the CBD group, and that association weakened across later timepoints.

Clinical Relevance: For patients using cannabis for chronic pain, this study supports a practical distinction between CBD-dominant and THC-containing products when cognition matters. In my view, CBD-dominant edibles may be the safer starting point for people who need to preserve working memory and day-to-day function, especially older adults or patients with cognitively demanding jobs. THC-containing products deserve more caution when counseling about driving, work performance, and other tasks that depend on short-term learning and attention.

The current research cohort reflects diverse investigations spanning Glucagon-like Peptide-1 Receptor Agonist-Associate, emphasizing rigorous study endpoints and reproducible methodologies across academic centers.

Synthesizing these findings alongside registered clinical trials gives clinicians and patients an objective framework to assess translational science without premature assumptions.

Tracking literature like Glucagon-like Peptide-1 Receptor Agonist-Associate is most valuable when we look past the excitement to the actual endpoints and patient population.

Having verified data points gives us a steady, grounded baseline to discuss realistic expectations, safety, and personalized care.

Three Rules for Critical Reading